KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Change in Account Payables: 2019-2024

Historic Change in Account Payables for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Dec 2024 value amounting to $6.4 million.

  • Recursion Pharmaceuticals' Change in Account Payables fell 289.29% to -$5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year increase of 154.24%. This contributed to the annual value of $6.4 million for FY2024, which is 751.98% up from last year.
  • As of FY2024, Recursion Pharmaceuticals' Change in Account Payables stood at $6.4 million, which was up 751.98% from -$987,000 recorded in FY2023.
  • Recursion Pharmaceuticals' 5-year Change in Account Payables high stood at $6.4 million for FY2024, and its period low was -$987,000 during FY2023.
  • Its 3-year average for Change in Account Payables is $2.4 million, with a median of $1.8 million in 2022.
  • In the last 5 years, Recursion Pharmaceuticals' Change in Account Payables skyrocketed by 1,043.24% in 2021 and then slumped by 155.86% in 2023.
  • Recursion Pharmaceuticals' Change in Account Payables (Yearly) stood at -$185,000 in 2020, then skyrocketed by 1,043.24% to $1.7 million in 2021, then increased by 1.26% to $1.8 million in 2022, then tumbled by 155.86% to -$987,000 in 2023, then spiked by 751.98% to $6.4 million in 2024.